186 related articles for article (PubMed ID: 35220932)
1. Metallic Nanoparticles: A New Frontier in the Fight Against Leishmaniasis.
Guerra RO; do Carmo Neto JR; de Albuquerque Martins T; Farnesi de-Assunção TS; Junior VR; de Oliveira CJF; Silva ACA; da Silva MV
Curr Med Chem; 2022; 29(26):4547-4573. PubMed ID: 35220932
[TBL] [Abstract][Full Text] [Related]
2. Biogenic silver nanoparticles inducing Leishmania amazonensis promastigote and amastigote death in vitro.
Fanti JR; Tomiotto-Pellissier F; Miranda-Sapla MM; Cataneo AHD; Andrade CGTJ; Panis C; Rodrigues JHDS; Wowk PF; Kuczera D; Costa IN; Nakamura CV; Nakazato G; Durán N; Pavanelli WR; Conchon-Costa I
Acta Trop; 2018 Feb; 178():46-54. PubMed ID: 29111137
[TBL] [Abstract][Full Text] [Related]
3. Metallic nanoparticles and treatment of cutaneous leishmaniasis: A systematic review.
Guerra RO; do Carmo Neto JR; da Silva PEF; Franco PIR; Barbosa RM; de Albuquerque Martins T; Costa-Madeira J; de Assunção TSF; de Oliveira CJF; Machado JR; Silva Teixeira LA; Rodrigues WF; Júnior VR; Silva ACA; da Silva MV
J Trace Elem Med Biol; 2024 May; 83():127404. PubMed ID: 38364464
[TBL] [Abstract][Full Text] [Related]
4. How I Approach Leishmaniasis: Diagnosis and Treatment in the United States.
Ness TE; Martin-Blais R; Weatherhead JE
J Pediatric Infect Dis Soc; 2022 Dec; 11(11):525-532. PubMed ID: 36043874
[TBL] [Abstract][Full Text] [Related]
5. A nanotechnology based new approach for chemotherapy of Cutaneous Leishmaniasis: TIO2@AG nanoparticles - Nigella sativa oil combinations.
Abamor ES; Allahverdiyev AM
Exp Parasitol; 2016 Jul; 166():150-63. PubMed ID: 27109311
[TBL] [Abstract][Full Text] [Related]
6. Exploring Innovative Leishmaniasis Treatment: Drug Targets from Pre-Clinical to Clinical Findings.
Santana W; de Oliveira SSC; Ramos MH; Santos ALS; Dolabella SS; Souto EB; Severino P; Jain S
Chem Biodivers; 2021 Sep; 18(9):e2100336. PubMed ID: 34369662
[TBL] [Abstract][Full Text] [Related]
7. Clinical Efficacy Associated with Enhanced Antioxidant Enzyme Activities of Silver Nanoparticles Biosynthesized Using
El-Khadragy M; Alolayan EM; Metwally DM; El-Din MFS; Alobud SS; Alsultan NI; Alsaif SS; Awad MA; Abdel Moneim AE
Int J Environ Res Public Health; 2018 May; 15(5):. PubMed ID: 29786651
[TBL] [Abstract][Full Text] [Related]
8. Leishmaniasis.
Herwaldt BL
Lancet; 1999 Oct; 354(9185):1191-9. PubMed ID: 10513726
[TBL] [Abstract][Full Text] [Related]
9. Application of nanotechnology in treatment of leishmaniasis: A Review.
Akbari M; Oryan A; Hatam G
Acta Trop; 2017 Aug; 172():86-90. PubMed ID: 28460833
[TBL] [Abstract][Full Text] [Related]
10. Use of liposomal nanoformulations in antileishmania therapy: challenges and perspectives.
Téllez J; Echeverry MC; Romero I; Guatibonza A; Santos Ramos G; Borges De Oliveira AC; Frézard F; Demicheli C
J Liposome Res; 2021 Jun; 31(2):169-176. PubMed ID: 32228210
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous and mucocutaneous leishmaniasis.
David CV; Craft N
Dermatol Ther; 2009; 22(6):491-502. PubMed ID: 19889134
[TBL] [Abstract][Full Text] [Related]
12. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis.
Goto H; Lindoso JA
Expert Rev Anti Infect Ther; 2010 Apr; 8(4):419-33. PubMed ID: 20377337
[TBL] [Abstract][Full Text] [Related]
13. Current treatment for cutaneous leishmaniasis: a review.
Palumbo E
Am J Ther; 2009; 16(2):178-82. PubMed ID: 19300044
[TBL] [Abstract][Full Text] [Related]
14. Polycaprolactone Antimony Nanoparticles as Drug Delivery System for Leishmaniasis.
Sousa-Batista AJ; Cerqueira-Coutinho C; do Carmo FS; Albernaz MS; Santos-Oliveira R
Am J Ther; 2019; 26(1):e12-e17. PubMed ID: 30601770
[TBL] [Abstract][Full Text] [Related]
15. Leishmaniasis.
Burza S; Croft SL; Boelaert M
Lancet; 2018 Sep; 392(10151):951-970. PubMed ID: 30126638
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
[TBL] [Abstract][Full Text] [Related]
17. Vaccines in leishmaniasis: advances in the last five years.
Brodskyn C; de Oliveira CI; Barral A; Barral-Netto M
Expert Rev Vaccines; 2003 Oct; 2(5):705-17. PubMed ID: 14711330
[TBL] [Abstract][Full Text] [Related]
18. Decanethiol functionalized silver nanoparticles are new powerful leishmanicidals in vitro.
Isaac-Márquez AP; Talamás-Rohana P; Galindo-Sevilla N; Gaitan-Puch SE; Díaz-Díaz NA; Hernández-Ballina GA; Lezama-Dávila CM
World J Microbiol Biotechnol; 2018 Feb; 34(3):38. PubMed ID: 29460068
[TBL] [Abstract][Full Text] [Related]
19. Some Scaffolds as Anti-leishmanial Agents: A Review.
Mahender T; Pankaj W; Kumar SP; Ankur V; Kumar SS
Mini Rev Med Chem; 2022; 22(5):743-757. PubMed ID: 34517799
[TBL] [Abstract][Full Text] [Related]
20. Intermediate/borderline disseminated cutaneous leishmaniasis.
Paniz Mondolfi AE; Duffey GB; Horton LE; Tirado M; Reyes Jaimes O; Perez-Alvarez A; Zerpa O
Int J Dermatol; 2013 Apr; 52(4):446-55. PubMed ID: 23231577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
